The Vyaderm Pharmaceuticals case outlines dilemmas facing a company that introduced EVA as a basis for setting performance related pay. The central challenge is deciding if the costs of strict adherence to the rules set out for bonus calculations are worth paying to avoid arguments over special exceptions and a dilution of the motivational effects of the objectivity of the calculations